---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-24-000039"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:28:06.996904+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics reports Q1 net loss $16.6M; positive Phase 3 presbyopia data, NDA on track mid-2024

## Summary
- Net loss $16.6M ($3.53/share) vs $12.7M ($6.50/share) in Q1 2023; cash $213.3M.
- Phase 3 CLARITY study for LNZ100 met all primary/secondary endpoints; 84% achieved ≥4 lines near vision improvement.
- NDA submission to FDA for LNZ100 planned for mid-2024; commercial launch as early as H2 2025.
- Completed merger with Graphite Bio and concurrent $53.5M private placement in March 2024.
- Jeff George appointed Chairman; Dan Chevallard CFO; commercial buildout underway including third-party logistics.

## SEC filing metadata
- accession: 0001815776-24-000039
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000039/0001815776-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000039/lenz-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-24-000039
- JSON: https://secwatch.observer/filing/0001815776-24-000039.json
- Plain text: https://secwatch.observer/filing/0001815776-24-000039.txt

## Key facts
- Earnings Releases
  LENZ Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 8, 2024, LENZ Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000039/0001815776-24-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.